Study on Warfarin Use and Cancer Incidence
Introduction to Warfarin
A recent study aimed to explore the potential link between warfarin use and reduced cancer incidence within a sizable Norwegian population. Warfarin sodium is the most widely prescribed anticoagulant worldwide, utilized by approximately 5% to 10% of adults for various medical conditions, including atrial fibrillation, prosthetic heart valves, and venous thromboembolism.
Background on Antitumor Potential
The antitumor effects of warfarin have been supported by several experimental cancer model studies. However, previous epidemiological research has yielded mixed results regarding the relationship between warfarin and cancer. Some studies have suggested a specific association with urogenital cancers, while others have found no significant correlation with cancer incidence.
Details of the Norwegian Study
A recent Norwegian study published in JAMA Internal Medicine examined this association using a nationwide cohort divided into two groups: warfarin users and nonusers. The subgroup of warfarin users included individuals taking the medication for atrial fibrillation or atrial flutter. Warfarin use was defined as having a prescription for at least six months and a minimum of two years from the first prescription to any cancer diagnosis.
Methodology and Findings
Researchers employed an incidence rate ratio (IRR) to evaluate cancer diagnosis rates among warfarin users compared to nonusers, where a lower IRR indicates a reduced rate of cancer. Among the 1,256,725 individuals in the cohort, 10.6% had cancer, with 7.4% identified as warfarin users and 92.6% as nonusers.
The warfarin users tended to be older, with a mean age of 70 years, and predominantly male, contrasting with nonusers who had a mean age of 64 years and were primarily female. The study revealed a significantly lower IRR for all cancer sites among warfarin users, particularly for organ-specific sites such as prostate and breast cancer, although no significant effect was observed for colon cancer.
Subgroup Analysis
In a subgroup analysis focusing on patients with atrial fibrillation or atrial flutter, the IRR was lower across all cancer sites (IRR of 0.62) and for prevalent sites, including lung (0.39), prostate (0.60), breast (0.72), and colon (0.71).
Conclusion and Implications
This study highlights the potential anticancer benefits of warfarin use among individuals over 50 years old. The findings suggest a lower incidence of cancer associated with warfarin, indicating a possible protective effect against cancer. These results could significantly influence medication choices for patients requiring anticoagulation therapy.
Author Information
Written by Dr. Swapna Aleti, Scientific Writer and Associate Professor.
References
1. Keeling D, et al. Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol. 2011;154(3):311-324.
2. Tadros R, Shakib S. Warfarin—indications, risks, and drug interactions. Aust Fam Physician. 2010;39(7):476-479.
3. Kirane A, et al. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Res. 2015;75(18):3699-3705.
4. Ryan JJ, et al. Reduced incidence of spontaneous metastases with long-term Coumadin therapy. Ann Surg. 1968;168(1):163-168.
5. Paolino M, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014;507(7493):508-512.
6. Williamson RC, et al. Effects of anticoagulation and ileal resection on the development and spread of experimental intestinal carcinomas. Br J Cancer. 1980;42(1):85-94.
7. Tagalakis V, et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol. 2007;8(5):395-402.
8. Kinnunen PT, et al. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2016;50(6):413-419.
9. Haaland GS, et al. Association of Warfarin Use with Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Internal Medicine. 2017;177(12):1774-1780.